Fundraising FoxPontifax Venture Capital — 2017 Investments
4 investments dated 2017 · listed companies and verified rows first · show all
Keros is a clinical-stage biopharmaceutical company developing product candidates that modulate signaling of the transforming growth factor-beta (TGF-β) family of proteins to treat disorders affecting blood cells and tissues such as bone, muscle, adipose and heart.
BiotechHealthtechLexington, US
Jasbir Seehra(Co-Founder, Chief Executive Officer and Director)in
BoardJulius Knowles(Director)Alon Lazarus(Director)inOhad Hammer(Director)Ran Nussbaum(Director)in
Co-investorsArkin CapitalForesite CapitalOrbiMed
Soligenix is a biopharmaceutical company developing treatments for rare diseases, with programs in photodynamic therapy for cutaneous T-cell lymphoma and psoriasis, immunomodulatory drugs for inflammatory conditions, and vaccine candidates for infectious diseases.
BiotechPrinceton, US
Richard C. Straube, MD MSc(Executive Officer)Karen Krumeich(Executive Officer)Oreola Donini, PhD(Executive Officer)Christopher J. Schaber(Executive Officer, Director)inAdam T. Rumage(Executive Officer)R. Christopher Cavalli, PhD(Executive Officer)
Co-investorsRidgeback Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.